Optimizing HIV prevention for highly vulnerable methamphetamine-using sexual minority men

Ended Cooperative Agreement Awarded Last action

Award ID
UG3AI169652
Recipient
Awarding agency
Obligated
$3,840,000

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Originally
Place of performance
New York, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
This lite-2 (RFA-AI-21-018) initiative responds to a resurgent epidemic of methamphetamine (meth) use in sexual minority men (SMM), which is a primary driver of HIV incidence. The overarching goals are two-fold: 1) identify multi-level and BIO-behavioral determinants of amplified HIV seroconversion risk in meth-using SMM; and 2) test the effectiveness of telehealth motivational enhancement interventions for optimizing entry or RE-entry of SMM who use meth into the prep care continuum. Findings from our lite-1 cohort (UG3/UH3 AI-133675, RFA-AI-16-031) and others provide compelling evidence that meth use is increasing, disproportionally impacts racial/ethnic minorities, and accounts for one-in-three new HIV infections in SMM. In response to lite-2 (RFA- AI-21-018) we propose a multi-component initiative zeroing in on the "where," "how," and "why" of meth use and HIV risk. Where: what are the geospatial determinants of the association of meth use with HIV incidence? How: how can we support (RE-)entry into the prep care continuum with this high priority population of SMM who use meth? Why: does meth amplify biological risk of HIV by potentiating rectal immune dysregulation? Aim 1: examine multi-level structural, psychological, and social determinants of amplified HIV seroconversion risk in SMM who use meth. The centerpiece of our lite-2 initiative is a new prospective, BIO-behavioral cohort with n=5,000 SMM (n=3,000 SMM who use meth, n=2,000 who do not). Participants will complete assessments over 36 months and provide biological samples for HIV testing, drug toxicology testing, rectal stis, and rectal cytokines/chemokines. Our primary goal will be to investigate the role of geospatial determinants (e.g., background meth and HIV prevalence, urbanicity) and other structural determinants (e.g., structural stigma of sexual minorities as evidenced by policies/laws) in relation to the association of meth use with amplified HIV seroconversion risk. Aim 2: test the comparative and combined effectiveness of telehealth motivational enhancement interventions for optimizing prep use. Prep readiness interventions for supporting motivation (prism) is a hybrid type i, modified factorial randomized controlled trial (RCT) of telehealth CM that provides incentives for filling a prep prescription, and a 2-session telehealth MI intervention that we adapted with meth- using SMM (R34-DA046367, carrico/grov). Prism will enroll 840 meth-using SMM who are not currently taking prep from the lite-2 cohort (aim 1) to examine the effectiveness of CM (n = 280), MI (n = 280), and MI+CM (n = 280) on the primary outcome - filling a prep prescription. Aim 3: determine whether greater rectal immune dysregulation partially explains amplified risk of HIV seroconversion in SMM who use meth. Using a case-cohort design, we will compare HIV seroconverters (n=450) with matched seronegative controls (n=450) to examine the clinical relevance of meth-induced alterations in rectal cytokines with respect to HIV seroconversion. This lite-2 initiative could have an exceptional impact by transforming HIV prevention with SMM.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $95,000
Amendment $95,000
Amendment $700,000
Amendment $500,000
Amendment $500,000
Amendment $700,000
Amendment $750,000
Original award $500,000
Show all 13

Subawards

Subrecipient Amount Awarded
Northern California Institute For Research And Education, Inc. Dr. Manuel’s responsibilities on this project will include training and supervising research staff in motivational interviewing. She will also train research… $17,749
University Of Florida American Transformative HIV Study (AMETHST) is a LITE milestone-driven and phased award. Phase I is a prospective, 36-month cohort study examining the… $19,148
The University Of Memphis As co-investigator Dr. Ray will be responsible for statistical analyses including the development, quality, accuracy, and implementation of statistical methods,… $11,033
The Trustees Of Columbia University In The City Of New York Statement of Work As Co-Investigator, Dr. Duncan will contribute to the development of study protocols for geo-spatial analysis, hire, train and oversee the… $59,958
Northern California Institute For Research And Education, Inc. Dr. Manuel’s responsibilities on this project will include training and supervising research staff in motivational interviewing. She will also train… $35,429
Florida International University Scope: Dr. Carrico and his staff will assist CUNY and Dr. Grov with the testing of the PRISM telehealth interventions involving the delivery of contingency… $564,415
University Of Florida American Transformative HIV Study (AMETHST) is a LITE milestone-driven and phased award. Phase I is a prospective, 36-month cohort study examining the… $42,852
University Of Miami Scope of Work This LITE-2 initiative has two distinct phases. Phase I is a prospective, 36-month bio-behavioral cohort study examining the multi-level… $800
The University Of Memphis As co-investigator Dr. Ray will be responsible for statistical analyses including the development, quality, accuracy, and implementation of statistical methods,… $11,592
The Administrators Of Tulane Educational Fund Regarding the proposed study entitled, “Optimizing HIV prevention for highly vulnerable methamphetamine using sexual minority men, � the Tulane… $65,852
The Trustees Of Columbia University In The City Of New York Statement of Work As Co-Investigator, Dr. Duncan will contribute to the development of study protocols for geo-spatial analysis, hire, train and oversee the… $66,864
Albert Einstein College Of Medicine Albert Einstein College of Medicine Scope of Work • Contribute to all aspects of the study, including development of the study protocol, study… $38,219
Florida International University Scope: Dr. Carrico and his staff will assist CUNY and Dr. Grov with the testing of the PRISM telehealth interventions involving the delivery of contingency… $245,174
University Of Miami Scope of Work This LITE-2 initiative has two distinct phases. Phase I is a prospective, 36-month bio-behavioral cohort study examining the multi-level… $241,173
Show all 14

Quick answers

Who received award UG3AI169652?

UG3AI169652 was awarded to Research Foundation Of The City University Of New York by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 8, 2022.

How much is award UG3AI169652 worth?

$3,840,000 has been obligated on UG3AI169652.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login